[go: up one dir, main page]

NO20080564L - Antitumorale biokonjugater av hyaluronsyre eller dens derivater oppnadd ved indirekte kjemisk konjugering, og deres anvendelse innen det farmasoytiske omradet - Google Patents

Antitumorale biokonjugater av hyaluronsyre eller dens derivater oppnadd ved indirekte kjemisk konjugering, og deres anvendelse innen det farmasoytiske omradet

Info

Publication number
NO20080564L
NO20080564L NO20080564A NO20080564A NO20080564L NO 20080564 L NO20080564 L NO 20080564L NO 20080564 A NO20080564 A NO 20080564A NO 20080564 A NO20080564 A NO 20080564A NO 20080564 L NO20080564 L NO 20080564L
Authority
NO
Norway
Prior art keywords
bioconjugates
hyaluronic acid
antitumoral
pharmaceutical field
chemical conjugation
Prior art date
Application number
NO20080564A
Other languages
English (en)
Inventor
Davide Renier
Fabio Bettella
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Publication of NO20080564L publication Critical patent/NO20080564L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende beskrivelse beskriver en ny gruppe av biokonjugater som kan oppnås ved hjelp av indirekte syntese, via en molekylær spacer, mellom hyaluronsyre og/eller dens derivater og legemidler med en antitumoral aktivitet som tilhører forskjellige grupper, deres fremstillingsprosesser og anvendelser innen det onkologiske området. De nye derivatene, i forhold til typen av binding og substitusjonsgrad, har ulike fysisk-kjemiske egenskaper som forbedrer deres tolererbarhet og effektivitet og som tillater en mer nøyaktig modulering av doseringen, med utnyttelse av en aktiv målrettingsmekanisme.
NO20080564A 2005-08-03 2008-01-30 Antitumorale biokonjugater av hyaluronsyre eller dens derivater oppnadd ved indirekte kjemisk konjugering, og deres anvendelse innen det farmasoytiske omradet NO20080564L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000242A ITPD20050242A1 (it) 2005-08-03 2005-08-03 Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
PCT/EP2006/007717 WO2007014784A2 (en) 2005-08-03 2006-08-02 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation

Publications (1)

Publication Number Publication Date
NO20080564L true NO20080564L (no) 2008-05-05

Family

ID=37038336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080564A NO20080564L (no) 2005-08-03 2008-01-30 Antitumorale biokonjugater av hyaluronsyre eller dens derivater oppnadd ved indirekte kjemisk konjugering, og deres anvendelse innen det farmasoytiske omradet

Country Status (19)

Country Link
US (1) US9687558B2 (no)
EP (4) EP2537533B1 (no)
JP (2) JP5457672B2 (no)
KR (1) KR101614157B1 (no)
CN (2) CN101267840B (no)
AU (1) AU2006274992B2 (no)
BR (1) BRPI0614536A2 (no)
CA (1) CA2616957C (no)
DK (2) DK2537533T3 (no)
ES (4) ES2633291T3 (no)
HK (1) HK1118011A1 (no)
IL (1) IL189078A0 (no)
IT (1) ITPD20050242A1 (no)
NO (1) NO20080564L (no)
NZ (1) NZ565504A (no)
PL (3) PL2540319T3 (no)
RU (1) RU2411958C2 (no)
SI (3) SI2537533T1 (no)
WO (1) WO2007014784A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006266741B2 (en) * 2005-07-06 2011-09-01 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
ITMI20071267A1 (it) * 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US8088412B2 (en) * 2008-01-30 2012-01-03 University Of Kansas Intralymphatic chemotherapy drug carriers
US20120100218A1 (en) * 2008-01-30 2012-04-26 Laird Forrest Intralymphatic Chemotherapy Drug Carriers
IT1391006B1 (it) * 2008-10-08 2011-10-27 Fidia Farmaceutici Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
WO2009130564A1 (en) * 2008-04-22 2009-10-29 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
KR20110032561A (ko) * 2009-09-23 2011-03-30 포항공과대학교 산학협력단 약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
CN102399295B (zh) 2010-09-09 2013-11-06 常州百瑞吉生物医药有限公司 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途
US20160074519A1 (en) * 2013-04-25 2016-03-17 Aluron Biopharma Inc. Crosslinked hyaluronic acid compositions
JPWO2015005459A1 (ja) * 2013-07-10 2017-03-02 生化学工業株式会社 呼吸器投与用の医薬組成物
CZ305153B6 (cs) * 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
CN104497167B (zh) * 2014-11-24 2017-05-17 山东省药学科学院 透明质酸衍生物及其治疗药物
CN105727305B (zh) * 2016-02-24 2018-09-07 温州医科大学 一种Legumain响应释放阿霉素缓释纳米制剂及制备方法与作为制备载体药物的应用
CN116650519A (zh) 2018-06-15 2023-08-29 克罗马药品有限责任公司 稳定化的透明质酸
CN108912245B (zh) * 2018-07-13 2020-04-28 吉林大学 一种具有靶向性和抗炎活性的氟化透明质酸衍生物及其制备方法和应用
US20220040318A1 (en) * 2018-09-28 2022-02-10 Seikagaku Corporation Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
WO2021252513A1 (en) * 2020-06-08 2021-12-16 Aihol Corporation Uses of hyaluronan conjugate
CN111892668B (zh) * 2020-07-03 2022-07-12 广东工业大学 一种化合物及其制备方法、荧光探针和抗肿瘤药物
CN112089690A (zh) * 2020-08-31 2020-12-18 厦门大学 一种透明质酸化青蒿琥酯、其纳米胶束制剂及其制备方法和用途
CN112608397B (zh) * 2020-11-30 2021-12-28 西安交通大学 一种铂类抗肿瘤药物-多糖聚合物纳米前药及制备方法和应用
KR20230112681A (ko) 2021-06-18 2023-07-27 아이홀 코포레이션 히알루로난 접합체의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
WO1992006714A1 (en) * 1990-10-18 1992-04-30 Shiseido Co., Ltd. Combination of hyaluronic acid with medicinal ingredient and production thereof
IT1247175B (it) 1991-04-19 1994-12-12 Fidia Spa Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5688931A (en) 1993-02-26 1997-11-18 Drug Delivery System Institute, Ltd. Polysaccharide derivatives and drug carriers
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
WO2001070275A2 (en) * 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
US20020197261A1 (en) 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA2445985A1 (en) 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Also Published As

Publication number Publication date
ES2633290T3 (es) 2017-09-20
US9687558B2 (en) 2017-06-27
DK2540319T3 (en) 2017-08-21
RU2411958C2 (ru) 2011-02-20
WO2007014784A2 (en) 2007-02-08
SI2537533T1 (sl) 2017-10-30
SI1909843T1 (sl) 2017-01-31
EP2540319B1 (en) 2017-05-10
NZ565504A (en) 2011-02-25
KR101614157B1 (ko) 2016-04-20
CN103041402A (zh) 2013-04-17
EP2537533B1 (en) 2017-05-17
EP1909843B1 (en) 2016-09-21
EP2540319A1 (en) 2013-01-02
EP2548582A1 (en) 2013-01-23
EP2537533A2 (en) 2012-12-26
WO2007014784A9 (en) 2007-07-12
ES2692619T3 (es) 2018-12-04
EP1909843A2 (en) 2008-04-16
RU2008102878A (ru) 2009-09-10
AU2006274992A1 (en) 2007-02-08
ITPD20050242A1 (it) 2007-02-04
SI2540319T1 (sl) 2017-08-31
US20080292703A1 (en) 2008-11-27
PL1909843T3 (pl) 2017-03-31
JP5457672B2 (ja) 2014-04-02
IL189078A0 (en) 2008-08-07
EP2548582B1 (en) 2018-09-19
PL2537533T3 (pl) 2017-10-31
WO2007014784A3 (en) 2007-05-18
CN101267840B (zh) 2015-07-08
KR20080032235A (ko) 2008-04-14
ES2633291T3 (es) 2017-09-20
CA2616957A1 (en) 2007-02-08
JP2009503010A (ja) 2009-01-29
JP2014001249A (ja) 2014-01-09
PL2540319T3 (pl) 2017-10-31
EP2537533A3 (en) 2013-01-09
HK1118011A1 (zh) 2009-01-30
AU2006274992B2 (en) 2012-03-08
CN101267840A (zh) 2008-09-17
ES2596877T3 (es) 2017-01-12
BRPI0614536A2 (pt) 2012-11-27
CA2616957C (en) 2016-04-26
DK2537533T3 (da) 2017-08-21

Similar Documents

Publication Publication Date Title
NO20080564L (no) Antitumorale biokonjugater av hyaluronsyre eller dens derivater oppnadd ved indirekte kjemisk konjugering, og deres anvendelse innen det farmasoytiske omradet
NO20084712L (no) Nye farmasoytiske forbindelser
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
NO20075229L (no) N-hydroksyamider omega-substituert med trisykliske grupper som histondeacetylasehemmere, deres fremstilling og anvendelse i farmasoytiske formuleringer
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
MX2010006005A (es) Sales de ingredientes activos con contraiones polimericos.
NZ724593A (en) Anti-cd70 antibody drug conjugates
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
NI201100070A (es) Una formulación farmacéutica que contiene el principio activo 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona.
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
NO20071504L (no) Pyrimidinderivanter.
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
BRPI0614761A2 (pt) proteìnas de fusão de albumina
TW200642700A (en) Chemically defined stabiliser
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
WO2008069917A3 (en) Novel cyclic peptides
EA201692376A1 (ru) Терапевтические конъюгаты с сульфатированными дендримерами для внутриклеточного нацеливания
CY1116801T1 (el) Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων
SG10201807904RA (en) Mitochondria-Targeted Dicarbonyl Sequestering Compounds
CY1113525T1 (el) Θεραπεια στοχευσης καθεψινης s
CY1122258T1 (el) Μεθοδος θεραπειας ή προφυλαξης απο τη βακτηριακη κολπιτιδα
WO2009111336A3 (en) Methods of purifying plasmid dna
CY1120101T1 (el) Παραγωγο πυριδονης και φαρμακο που το περιεχει

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application